Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Johnson & Johnson    JNJ   US4781601046


News SummaryMost relevantAll newsSector news 

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

05/17/2012 | 01:41pm US/Eastern
   By Peter Loftus 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website:

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581;

React to this article
Latest news on JOHNSON & JOHNSON
05/23 JOHNSON & JOHNSON : 6 A plan by the makers
05/23 JOHNSON & JOHNSON : A plan by the makers ; CITY DESK
05/22 JOHNSON & JOHNSON : STELARA® Receives CHMP Positive Opinion For Treatment Of Ado..
05/22 JOHNSON & JOHNSON : SIMPONI® Receives CHMP Positive Opinion For Treatment Of Non..
05/22 JOHNSON & JOHNSON : Pharmaceutical Segment to Continue Driving Above-Industry Gr..
05/22 JOHNSON & JOHNSON : UK watchdog says Reckitt's K-Y buy could hurt competition
05/22 RECKITT BENCKISER : Press release: CMA sets out provisional concerns over lubric..
05/22DJRECKITT BENCKISER : Personal Lubricants Buy May Lessen Competition -UK Regulator
05/21 JOHNSON & JOHNSON : JNJ) Closes 0.42% Down on the Day for May 21
05/21 JOHNSON & JOHNSON : Risperdal Lawyers at Bernstein Liebhard LLP Look Ahead to Ju..
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Income Statement Evolution
More Financials